Business Lawsuit settlement

Novartis Settles HeLa Cell Lawsuit

Analysis based on 14 articles · First reported Feb 24, 2026 · Last updated Feb 26, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The settlement by Novartis, following a similar one by Thermo Fisher Scientific, sets a precedent for other pharmaceutical and biotechnology companies facing lawsuits from the Estate of Henrietta Lacks. This could lead to increased legal costs and potential financial liabilities for companies that have commercialized products using HeLa cells, impacting their valuations and future R&D strategies.

Pharmaceuticals Biotechnology Healthcare

Event Summary

Novartis has reached an undisclosed settlement with the Estate of Henrietta Lacks, resolving a lawsuit that alleged the pharmaceutical giant unjustly profited from HeLa cells. These cells were taken from Henrietta Lacks' tumor in 1951 without her knowledge and became the first immortal human cell line, crucial for numerous medical advancements including vaccines and genetic mapping. This is the second such settlement for the Estate of Henrietta Lacks, following an agreement with Thermo Fisher Scientific in 2023. Other lawsuits against Ultragenyx and Viatris remain active. The case highlights historical racial injustices in the medical system and raises questions about compensation for the commercial use of biological materials obtained without consent.

Key Actions

95 Novartis settled lawsuit Henrietta Lacks

90 Henrietta Lacks filed lawsuit Novartis

80 Thermo Fisher Scientific settled lawsuit Henrietta Lacks

70 Henrietta Lacks filed lawsuit Ultragenyx

70 Henrietta Lacks filed lawsuit Viatris

Entities Involved

per

Henrietta Lacks

Henrietta Lacks' cells, taken without her consent in 1951, became the foundational HeLa cell line, crucial for numerous medical advancements. Her estate has now settled a lawsuit with Novartis, seeking compensation for the unauthorized commercialization of these cells.

Importance 100 Sentiment 50

stock

Novartis

Novartis has settled a lawsuit with the Estate of Henrietta Lacks regarding the unauthorized use of HeLa cells. The settlement terms are confidential, but it resolves a claim of unjust enrichment, potentially mitigating further legal and reputational risks for Novartis.

Importance 90 Sentiment 10

stock

Thermo Fisher Scientific

Thermo Fisher Scientific previously reached an undisclosed settlement with the Estate of Henrietta Lacks in 2023 over similar claims of unjust enrichment from the commercialization of HeLa cells. This settlement set a precedent for the current Novartis agreement.

Importance 60 Sentiment 10

stock

Ultragenyx

Ultragenyx is currently facing an active lawsuit from the Estate of Henrietta Lacks, alleging the company profited from using HeLa cells in its gene therapy products. The settlements with Novartis and Thermo Fisher Scientific may influence the outcome of this ongoing litigation.

Importance 50 Sentiment 0

stock

Viatris

Viatris is also involved in active litigation with the Estate of Henrietta Lacks, facing claims of unjust enrichment from the use of HeLa cells in its pharmaceutical products. The settlement by Novartis could set a precedent for Viatris's case.

Importance 50 Sentiment 0

priv

Johns Hopkins Hospital

Johns Hopkins Hospital took Henrietta Lacks' cervical cells in 1951 without her knowledge. While the hospital states it never sold or profited from the HeLa cell lines, its historical involvement is central to the origin of the legal disputes.

Importance 30 Sentiment 0

per

Rebecca Skloot

Rebecca Skloot authored 'The Immortal Life of Henrietta Lacks,' a bestselling book that brought global attention to Henrietta Lacks' story and the ethical issues surrounding the use of her cells.

Importance 10 Sentiment 0

+ 1 more entities View on Dashboard

Relationships

Henrietta Lacks related ↔ Novartis

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard